# INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

> **NCT03277352** · PHASE1,PHASE2 · TERMINATED · sponsor: **Incyte Biosciences International Sàrl** · enrollment: 10 (actual)

## Conditions studied

- Advanced Malignancies
- Metastatic Cancer

## Interventions

- **DRUG:** INCAGN01876
- **DRUG:** Epacadostat
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03277352
- **Lead sponsor:** Incyte Biosciences International Sàrl
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-21
- **Primary completion:** 2020-07-01
- **Final completion:** 2020-07-01
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** The study was terminated due to emergent data from another study and unrelated to safety.
- **Last updated:** 2021-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03277352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03277352, "INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03277352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*